ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Enliven Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$38.70+1.38 (+3.70%)

Close on Oct 19, 2026

Market cap: $2.56B
P/E (TTM): –
Dividend yield: –

Enliven Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	99	124	100	76	110	48	5.02	7.38
Short-Term Investments	364	189	153	0	42	41	24	–
Cash & Short-Term Investments	463	313	253	76	90	88	29	7.38
Prepaid Expenses & Other	12	4.63	2.95	2.22	2.42	2.18	1.72	–
Total Current Assets	475	318	266	78	93	90	31	–
Property, Plant & Equipment	0.03	0.46	0.74	0.89	0.25	0.35	0.44	–
Gross Property, Plant & Equipment	0.26	1.38	1.41	1.26	0.48	0.48	0.48	–
Accumulated Depreciation	-0.23	-0.92	-0.67	-0.37	-0.23	-0.13	-0.03	–
Long-Term Investments	–	–	–	0	–	–	–	–
Operating Lease Right-of-Use Assets	0.38	0	0.32	0.63	0.53	–	–	–
Other Long-Term Assets	0.66	7.18	4.09	0	0.18	0.09	2.23	–
Total Assets	476	326	272	83	94	91	33	–
Accounts Payable	2.16	1.34	0.53	3.44	2.36	1.97	1.66	–
Accrued Expenses	–	–	–	1.68	4.60	4.28	2.54	–
Current Portion of Leases	0.40	–	0.34	–	0.25	–	–	–
Total Current Liabilities	17	16	26	9.72	7.21	6.25	4.20	–
Long-Term Leases	0	–	0	–	0.41	–	–	–
Operating Lease Liabilities	0.40	–	0.34	–	0.65	–	–	–
Other Long-Term Liabilities	0	0	0.07	0.66	–	–	–	–
Total Liabilities	17	16	26	10	7.62	6.41	4.38	–
Preferred Stock	0	0	0	–	–	–	–	–
Common Stock	0.06	0.05	0.04	0.00	0.03	0.02	0.00	–
Additional Paid-In Capital	806	553	400	6.04	234	181	5.87	–
Retained Earnings	-347	-243	-154	-83	-147	-96	-55	–
Comprehensive Income & Other	0.33	0.06	0.14	0	-0.02	0.00	0.03	–
Shareholders' Equity	460	310	246	-77	-43	84	-49	-26
Total Equity	460	310	246	-77	-43	84	-49	-26
Total Liabilities & Equity	476	326	272	83	94	91	33	–
Shares Outstanding(shares)	59	49	41	3.57	3.15	2.11	0.08	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -27.0%

Financial strength

Current ratio: 64.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 956.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.86
Dividend yield: –